BR112018068523A2 - new polysaccharide-protein conjugates and process to obtain the same - Google Patents

new polysaccharide-protein conjugates and process to obtain the same

Info

Publication number
BR112018068523A2
BR112018068523A2 BR112018068523A BR112018068523A BR112018068523A2 BR 112018068523 A2 BR112018068523 A2 BR 112018068523A2 BR 112018068523 A BR112018068523 A BR 112018068523A BR 112018068523 A BR112018068523 A BR 112018068523A BR 112018068523 A2 BR112018068523 A2 BR 112018068523A2
Authority
BR
Brazil
Prior art keywords
protein conjugates
polysaccharide
same
relates
present
Prior art date
Application number
BR112018068523A
Other languages
Portuguese (pt)
Inventor
Gill Davinder
Dalal Juned
Kumar Chhikara Manoj
Rana Rakesh
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt Ltd filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Publication of BR112018068523A2 publication Critical patent/BR112018068523A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a novos conjugados de polissacarídeo-proteína e ao processo para obtenção dos mesmos. mais particularmente, a presente invenção se refere a conjugados de polissacarídeo-proteína produzidos usando química de carbamato capazes de serem usados na produção de vacina monovalente ou vacinas combinadas multivalentes, assim como uma ferramenta diagnóstica. mais especificamente, a presente invenção se refere a conjugado de polissacarídeo-proteína carreadora de sorogrupo x, a, c, y e w135 de neisseria meningitidis usando química de carbamato e o processo para obtenção dos mesmos.The present invention relates to novel polysaccharide-protein conjugates and the process for obtaining them. more particularly, the present invention relates to polysaccharide-protein conjugates produced using carbamate chemistry capable of being used in the production of monovalent or multivalent combined vaccines, as well as a diagnostic tool. more specifically, the present invention relates to neisseria meningitidis serogroup x, a, c, y and w135 polysaccharide carrier protein conjugate using carbamate chemistry and the process for obtaining them.

BR112018068523A 2016-03-15 2017-03-10 new polysaccharide-protein conjugates and process to obtain the same BR112018068523A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611008901 2016-03-15
PCT/IB2017/051408 WO2017158480A1 (en) 2016-03-15 2017-03-10 Novel polysaccharide-protein conjugates and process to obtain thereof

Publications (1)

Publication Number Publication Date
BR112018068523A2 true BR112018068523A2 (en) 2019-01-22

Family

ID=59851687

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068523A BR112018068523A2 (en) 2016-03-15 2017-03-10 new polysaccharide-protein conjugates and process to obtain the same

Country Status (9)

Country Link
JP (1) JP2019508468A (en)
KR (1) KR102428253B1 (en)
CN (1) CN108883192A (en)
AU (1) AU2017234319B2 (en)
BR (1) BR112018068523A2 (en)
MX (1) MX2018010920A (en)
RU (1) RU2758090C2 (en)
WO (1) WO2017158480A1 (en)
ZA (1) ZA201806043B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901394XA (en) 2016-09-02 2019-03-28 Sanofi Pasteur Inc Neisseria meningitidis vaccine
WO2019003238A1 (en) * 2017-06-27 2019-01-03 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel multivalent polysaccharide – protein conjugate vaccine composition and formulation thereof
CN110652585B (en) * 2018-10-26 2023-05-26 武汉博沃生物科技有限公司 Polysaccharide-protein conjugate immune preparation and application thereof
CN110302375A (en) * 2019-06-27 2019-10-08 康希诺生物股份公司 A kind of glycoconjugate and application thereof
RU2770877C1 (en) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Method of producing antigenic conjugated substance of haemophilic type b microbe for creating vaccine preparations
CN114965784B (en) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 Method for measuring polysaccharide activation degree

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
RU2233172C2 (en) * 1997-07-17 2004-07-27 Бакстэ Хелскеа С.А. Haemophilus influenzae immunogenic conjugate polysaccharide - porin of meningococcus group b (variants), method for its preparing, pharmaceutical composition and method for immune response induction in animal with regards to haemophilus influenzae
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
US8431136B2 (en) * 2005-06-27 2013-04-30 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN1709505B (en) * 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 Polyvalent bacteria capsule polysaccharide-protein conjugate combined vaccine
AU2010301043B2 (en) * 2009-06-22 2014-01-09 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CA2863178C (en) * 2012-01-30 2021-04-06 Serum Institute Of India Ltd. Immunogenic composition
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines

Also Published As

Publication number Publication date
MX2018010920A (en) 2019-03-06
AU2017234319B2 (en) 2021-11-04
ZA201806043B (en) 2019-05-29
RU2018135066A (en) 2020-04-06
RU2018135066A3 (en) 2020-11-10
WO2017158480A1 (en) 2017-09-21
KR20180121564A (en) 2018-11-07
CN108883192A (en) 2018-11-23
JP2019508468A (en) 2019-03-28
KR102428253B1 (en) 2022-08-02
RU2758090C2 (en) 2021-10-26
AU2017234319A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
BR112018068523A2 (en) new polysaccharide-protein conjugates and process to obtain the same
BR112020004410A8 (en) PROCESSES FOR THE FORMULATION OF PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
BR112016016580A2 (en) CAPSULAR POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF
TR201900753T4 (en) Method for producing saccharide fiber.
MX2021015775A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof.
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112019001995A2 (en) multivalent pneumococcal polysaccharide conjugate composition? protein
BR112014003285A2 (en) sweet flavor modifier
BR112020004396A8 (en) PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
AR090294A1 (en) NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS OF THE SAME
BR112014031613A2 (en) process for preparing antibody conjugates and antibody conjugates
BRPI0813307C1 (en) immunogenic composition, vaccine, and, process to manufacture the vaccine
BR112012007876A2 (en) "ion exchange membranes"
BR112015023797A2 (en) dual specificity binding proteins directed against il-1b and / or il-17
BR112014015851A2 (en) double specific binding proteins directed against il-13 and / or il-17
IN2014DN09791A (en)
BR112021024393A8 (en) AN IMMUNOGENIC SEROTYPE 35B PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE AND CONJUGATION PROCESS FOR MANUFACTURING THE SAME
AR092897A1 (en) IMMUNOGENIC COMPOSITIONS
BR112015008419A8 (en) immunogenic composition, vaccine, and use of an immunogenic composition or vaccine
MX2016003621A (en) Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3.
BR112017006447A2 (en) conjugation process and synthetic oligosaccharide-protein conjugates obtained from the same
CY1123600T1 (en) METHOD OF TREATMENT
EA202090319A1 (en) PEPTIDE CONJUGATES, CONJUGATION METHOD AND THEIR USE
BR112018017174A2 (en) amino acid and peptide conjugates and conjugation process
BR112012007877A2 (en) means and methods for producing artificial capsular polysaccharides of neisseria meningitidis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2765 DE 02-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.